155 related articles for article (PubMed ID: 8285617)
1. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.
Klemens SP; DeStefano MS; Cynamon MH
Antimicrob Agents Chemother; 1993 Nov; 37(11):2344-7. PubMed ID: 8285617
[TBL] [Abstract][Full Text] [Related]
2. Activity of levofloxacin in a murine model of tuberculosis.
Klemens SP; Sharpe CA; Rogge MC; Cynamon MH
Antimicrob Agents Chemother; 1994 Jul; 38(7):1476-9. PubMed ID: 7979275
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
4. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.
Cynamon MH; Zhang Y; Harpster T; Cheng S; DeStefano MS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2922-4. PubMed ID: 10582883
[TBL] [Abstract][Full Text] [Related]
5. Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis.
Rastogi N; Ross BC; Dwyer B; Goh KS; Clavel-Sérès S; Jeantils V; Cruaud P
Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):901-7. PubMed ID: 1362540
[TBL] [Abstract][Full Text] [Related]
6. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
[TBL] [Abstract][Full Text] [Related]
7. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis].
Lu Y; Wang B; Zhao WJ; Zheng MQ; Li P; Fu L; Liang BW
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Sep; 33(9):675-8. PubMed ID: 21092635
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
9. Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility.
Klemens SP; Sharpe CA; Cynamon MH
Antimicrob Agents Chemother; 1996 Jan; 40(1):14-6. PubMed ID: 8787871
[TBL] [Abstract][Full Text] [Related]
10. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.
Lalande V; Truffot-Pernot C; Paccaly-Moulin A; Grosset J; Ji B
Antimicrob Agents Chemother; 1993 Mar; 37(3):407-13. PubMed ID: 8384811
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of second-line antituberculosis drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis complex isolates by E-test method].
Şimşek H; Tarhan G; Cesur S
Mikrobiyol Bul; 2015 Jan; 49(1):47-55. PubMed ID: 25706730
[TBL] [Abstract][Full Text] [Related]
12. Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection.
Shoen CM; DeStefano MS; Cynamon MH
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S288-90. PubMed ID: 10875802
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.
Rastogi N; Labrousse V; Goh KS
Curr Microbiol; 1996 Sep; 33(3):167-75. PubMed ID: 8672093
[TBL] [Abstract][Full Text] [Related]
14. Activity of twelve second-line antimicrobial agents against Mycobacterium tuberculosis in Taiwan.
Lu PL; Peng CF; Hwang JJ; Chen YH
J Chemother; 2008 Apr; 20(2):202-7. PubMed ID: 18467246
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
Tyagi S; Nuermberger E; Yoshimatsu T; Williams K; Rosenthal I; Lounis N; Bishai W; Grosset J
Antimicrob Agents Chemother; 2005 Jun; 49(6):2289-93. PubMed ID: 15917523
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of efficacy in vivo.
Harth G; Horwitz MA
Infect Immun; 2003 Jan; 71(1):456-64. PubMed ID: 12496196
[TBL] [Abstract][Full Text] [Related]
17. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.
Toungoussova OS; Mariandyshev AO; Bjune G; Caugant DA; Sandven P
Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):202-6. PubMed ID: 15742171
[TBL] [Abstract][Full Text] [Related]
18. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
[TBL] [Abstract][Full Text] [Related]
19. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Cynamon MH; Klemens SP; Sharpe CA; Chase S
Antimicrob Agents Chemother; 1999 May; 43(5):1189-91. PubMed ID: 10223934
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.
Vicente E; Villar R; Burguete A; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
Antimicrob Agents Chemother; 2008 Sep; 52(9):3321-6. PubMed ID: 18625764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
